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1. Introduction 
Envenomings by snakebites constitute a highly relevant public health problem on a world 
wide basis, particularly in tropical regions of Africa, Asia and Latin America (Gutiérrez et 
al., 2006; WHO, 2007a). It affects mostly agricultural workers and their children living in 
rural settings. Thus, its highest impact occurs in poor and politically underpowered people, 
thus representing a ‘disease of poverty’ (Harrison et al., 2009) which fulfils the 
characteristics of a truly neglected tropical disease. Accordingly, the World Health 
Organization (WHO) incorporated, in 2009, snakebite envenoming in its list of neglected 
tropical diseases (www.who.int/neglected_disease/diseases/en). Despite the high impact 
of this pathology in terms of morbidity and mortality in vast regions of the world, it has 
received little attention from international health agencies and foundations, research 
agendas, and pharmaceutical companies, even when compared with other neglected 
diseases which have received a well deserved growing attention over the last decade 
(Williams et al., 2010). Such low concern for an important disease is due in part to the lack of 
political voice of the groups affected by snakebites, to the weakening of public health 
systems in many developing countries, and to the poor documentation of the actual global 
impact of this problem, which makes the advocacy to confront this neglected disease a 
difficult task. The present chapter reviews the main features associated with snakebite 
envenoming and its treatment, and highlights some of the most pressing tasks that need to 
be undertaken to confront this public health problem.   
2. Assessing the actual impact of snakebite envenoming 
The actual incidence and mortality associated with snakebite envenoming is poorly known, 
in part due to the lack of reliable information on this disease in many regions of the world. 
Although health statistics, based on the reports of hospital cases to health authorities, are 
satisfactory in some countries (for example in Brazil, de Oliveira et al., 2009), for many 
countries and regions this information is largely deficitary (Gutiérrez et al., 2010b; WHO, 
2007a). This is in part due to the fact that health statistics are poor in many countries, and 
also that many people affected by snakebites do not seek medical attention and instead rely 
on local traditional healers, thus remaining invisible to health authorities (Habib et al., 2001; 
Michael et al., 2010; Otero et al., 2000; Sharma et al., 2004). Despite these limitations, a 
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number of studies have generated valuable information on the real impact of snakebite 
envenoming. Snakebites affect mainly agricultural workers and their relatives, living in poor 
rural settings of Africa, Asia and Latin America (Alirol et al., 2010; Chippaux, 2010; Fan & 
Cardoso, 1995; Warrell, 2010). Thus, it is clearly an occupational hazard. Incidence is usually 
higher in men than women, and children are also affected mostly due to their involvement 
in agricultural duties. Most bites occur in lower limbs, although bites in hands are also 
frequent (Alirol et al., 2010; Warrell, 2010). Incidence varies along the year, associated with 
the rainy season and with the timing of agricultural activities (Chippaux, 2010). Natural 
disasters have been associated with increments in the number of snakebites, as shown in 
Bangladesh during the 2007 monsoon flood (Alirol et al., 2010). Some social and ethnic 
groups are affected to a higher extent by snakebites, as compared with other groups. In 
Latin America, for instance, indigenous groups present a high incidence of snakebites 
(Larrick et al., 1978; Pierini et al., 1996). In addition, these groups are generally more 
vulnerable owing to their limited access to health services, evidencing a pattern of inequity 
that has implications in terms of mortality and morbidity secondary to snakebite 
envenomings (Gutiérrez, 2011). Moreover, these accidents fuel a vicious circle of poverty, 
since they have a negative impact on the working performance of agricultural workers, thus 
affecting the already precarious source of income for their families. Thus, in addition of 
being a disease of the poor (Harrison et al., 2009), snakebites worsens the economic situation 
of victims and their families. 
A pioneer study on mortality due to this pathology was conducted by Swaroop & Grab 
(1954) on the basis of hospital statistics. Chippaux (1998) estimated an annual total of 
5,400,000 bites, over 2,500,000 envenomings and 125,000 deaths due to snakebites. A more 
recent study by Kasturiratne et al. (2008) estimated a global total of envenomings ranging 
from 421,000 to 1,841,000, with fatalities ranging from 20,000 to 94,000. These studies 
presented estimations of envenomings and fatalities by regions as well. South and Southeast 
Asia present the highest incidence of snakebites, followed by sub-Saharan Africa 
(Kasturiratne et al., 2008). Likewise, these three regions have the highest numbers of 
fatalities. However, these estimates were based on the extrapolation of data from some 
regions and countries and, therefore, have limitations. When community-based surveys 
have been performed, the picture that emerges is one of a much higher dimension, both in 
terms of incidence and mortality (Snow et al., 1994; Sharma et al., 2004; Trape et al., 2001). 
The incidence of snakebites in specific areas can be very high. Examples are the Benue valley 
of Nigeria (497 per 100,000 population per year, Pugh & Theakston, 1980) and in 
southeastern Nepal (1,162 per 100,000 population per year, Sharma et al., 2004). A meta-
analysis of snakebites in Africa suggested that the actual incidence might be 3-5 times higher 
than that derived from hospital statistics (Chippaux, 2011). Two recent studies further 
illustrate this concept. A community-based survey performed in rural Bangladesh revealed 
an incidence of 623.4 cases per 100,000 population per year (Rahman et al., 2010), which is 
much higher than the incidence derived from hospital-based statistics. Moreover, a recent 
study on mortality in India, which was part of a large national representative mortality 
survey, indicates that there are 45,900 deaths due to snakebite envenoming per year in this 
country (Mohapatra et al., 2011). The issue of underreporting needs to be addressed by 
different approaches, such as by identifying regions where underreport is more likely to 
occur (Hansson et al., 2010), and by performing community-based surveys in countries of 
high incidence of snakebites.  
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2.1 Beyond mortality: The impact of sequelae from snakebite envenomings 
Case fatality rate in snakebite envenomings, if not properly treated, can be very high, 
especially in bites inflicted by highly venomous species (Sharma et al., 2004; Warrell, 
2010). In addition, a percentage of people that survive develop sequelae as a consequence 
of envenoming. In the case of bites by viperid snakes, and by some elapids (genus Naja) 
that induce local tissue necrosis, sequelae include tissue loss and dysfunction, which may 
lead to amputation (S.B. Abubakar et al., 2010a; Gutiérrez & Lomonte, 2009; Otero et al., 
2002; Warrell, 2010). Despite the scarcity of statistics on the incidence of sequelae 
following snakebite, observations in sub-Saharan Africa indicate that up to 20% of the 
patients, perhaps more, develop permanent physical sequelae (Pugh et al., 1980; Snow et 
al., 1994). Bites in the hands by viperid species are more prone to leave permanent tissue 
damage than bites in the lower limbs (Dart et al., 1992). Moreover, people suffering 
snakebites also present psychological sequelae, as clearly revealed by a recent study in Sri 
Lanka (S.S. Williams et al., 2011). The combination of physical and psychological 
consequences of snakebites has a dramatic impact on the quality of life of both patients 
and dependants. These are mostly poor agricultural workers whose survival depends 
very much on their physical and emotional stability to confront everyday hardships. In 
many cases, a large group of people depend on them as the only source of income. 
Therefore, when snakebite envenomings are analyzed using the parameter of DALYs 
(‘disability adjusted life years’) lost, the actual impact of this disease becomes more 
evident. It is necessary to investigate the effects of this pathology from such broader 
perspective, through interdisciplinary research projects involving international 
partnerships and networks.  
In order to have a more rigorous and realistic assessment of the actual dimension of 
snakebite envenoming worldwide, the following tasks should be implemented: (a) 
Introducing compulsory notification of these envenomings. (b) Implementing the use in 
death certification of the specific classifier T 63.0 snake venom listed in the International 
Statistical Classification of Diseases and Related Health Problems (WHO, 2007b). (c) 
Performing well-designed epidemiological research based on health statistics and 
community-based surveys. (d) Supporting the training of health staff for proper record 
keeping on snakebite envenoming in many countries. These and related efforts will 
contribute to the generation of a solid body of information which will help to raise 
awareness on the seriousness of this problem and, at the same time, will provide decision-
makers with more accurate data for the design of interventions of various sorts (Gutiérrez 
et al., 2010b).   
3. Snake species responsible for the highest toll of envenomings 
Snakes capable of inducing serious envenoming in humans are classified in the families 
Colubridae (sensu lato), Atractaspididae, Elapidae and Viperidae. These families include 
more than 2,600 species, although a relatively reduced number of them, mostly belonging to 
the families Elapidae and Viperidae, are responsible for the vast majority of snakebite 
envenomings worldwide (Warrell, 2010). In Asia, the most relevant species belong to the 
elapid genera Bungarus (kraits) and Naja (cobras) (Figure 1A), and to various species of the 
viperid genera Echis, Daboia, Trimeresurus and Hypnale (Warrell, 1995a).  In Africa, species of 
Naja and few viperids are important in the northern countries, whereas the saw-scale viper 
www.intechopen.com
 
Public Health – Methodology, Environmental and Systems Issues 
 
134 
(Echis ocellatus) (Figure 1B) inflicts a heavy toll in the sub-Saharan region, together with 
other viperids classified in the genera Echis and Bitis, and some cobras (Naja sp) (WHO, 
2010b). In the Americas, species of rattlesnakes (Crotalus) are important in North America, 
whereas lance-head vipers of the genus Bothrops, such as B. asper (Figure 1C) and B. atrox, are 
responsible for most snakebites in Central and South America, in addition to a number of 
Bothrops species in South America (Fan & Cardoso, 1995; Gómez & Dart, 1995; Gutiérrez, 2010).  
 
 
Fig. 1A. Naja naja from Sri Lanka. Photo: Mark O’Shea. Reprinted from Journal of Proteomics 
74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
 
 
Fig. 1B. Echis ocellatus from Togo. Photo: David Williams. Reprinted from Journal of 
Proteomics 74, 1735-1767, Williams et al., copyright 2011, with permission from Elsevier. 
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Fig. 1C. Bothrops asper from Costa Rica. Photo: Mahmood Sasa. From Gutiérrez et al. (2006) 
PLoS Medicine 3: e150. 
In addition, some species, albeit not causing high numbers of bites, are capable of inflicting 
severe envenomings, such as Lachesis sp (bushmaster) and Micrurus sp (coral snakes) in the 
Americas (Warrell, 2004), Atractaspis sp (borrowing snakes) and Dendroaspis sp (mambas) in 
Africa/Middle East (WHO, 2010b), and a variety of elapid species in Australia and Papua 
New Guinea (White, 2010). Envenomings by colubrid species are usually not severe 
although fatal cases by species of the African genera Dispholidus and Thelotornis have been 
described (Warrell, 1995b). The taxonomy of venomous snakes is a highly dynamic field  
and recent modifications have been introduced in medically-relevant snake taxa (Quijada-
Mascareñas & Wüster, 2010). Toxinologists, clinicians and antivenom manufacturers  
should be aware of these changes in taxonomy. Detailed information on the country 
distribution of the most important poisonous snakes is available at the WHO website 
http://apps.who.int/bloodproducts/snakeantivenoms/database/ 
4. Snake venom biochemistry and toxicology 
These groups of ‘advanced’ snakes have acquired, through a long and complex evolutionary 
history (Fry et al., 2006, 2009), the ability to synthesize a toxic secretion, i.e. venom, by an 
exocrine gland located in the maxillary region, together with a venom delivery system based 
on the presence of ducts and fangs (Meier & Stocker, 1995; Vonk et al., 2008). The molecular 
evolution of venom toxins has involved an accelerated Darwinian process, by which genes 
have been duplicated and recruited in venom glands, with a concomitant process of 
acquisition of toxic functions based on a trend to generate mutations in sequences coding 
predominantly for amino acid residues located in the surface of these proteins, as well as 
other molecular mechanisms such as domain loss and neofunctionalization, thus generating 
a wide versatility in their ability to interact with diverse tissue targets (Casewell et al., 2011; 
Fry et al., 2006; Kini & Chan, 1999; Ohno et al., 2003). In the last decade, the use of proteomic 
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tools based on mass spectrometric analysis and sequence determination has allowed a 
detailed knowledge on the composition of venoms from many species (Calvete et al., 2007; 
Calvete, 2010; Fox & Serrano, 2008). Understanding the snake venom proteomes (‘venomes’) 
provides valuable information for the search of novel toxins and for the design of the most 
appropriate mixtures of venoms for animal immunization for antivenom production, among 
other applications (Calvete, 2010; Gutiérrez et al., 2009a). 
Venoms from snakes of the family Elapidae comprise a high percentage of proteins of the 
so-called ‘three finger toxin’ family, which are low molecular mass (6-9 kDa) polypeptides 
that exert a number of actions, such as the ability to block neuromuscular junctions at the 
post-synaptic level by binding with very high affinity to the nicotinic cholinergic receptor of 
the motor end-plate in skeletal muscle fibers (Hegde et al., 2010). Some three-finger toxins 
are membrane-disorganizing proteins, named ‘cardiotoxins’ or ‘cytotoxins’, which disrupt 
the integrity of cell membranes and are likely to play a role in the tissue damage associated 
with envenoming by some cobras (Dufton & Hider, 1988). The venoms of Dendroaspis sp 
(mambas) contain other types of neurotoxins, i.e. dendrotoxins and fasciculins, which 
interfere with neuromuscular junctions by various mechanisms (Harvey, 2001, 2010). Elapid 
venoms are also characterized by the high abundance of phospholipases A2 (PLA2s), some of 
which are potent neurotoxins whose mechanism of action relies in the specific binding to 
receptors in the presynaptic nerve terminal, followed by degradation of phospholipids at 
the plasma membrane of these terminals, thus affecting the normal process of 
neurotransmitter release (Rossetto et al., 2006). Other PLA2s induce acute muscle damage 
which, in the case of some sea snakes and other elapids, results in systemic myotoxicity, i.e. 
rhabdomyolisis, associated with myoglobinuria, hyperkalemia and acute renal failure 
(Gutiérrez & Ownby, 2003). Besides the predominant three-finger toxins and PLA2s, elapid 
venoms also contain other proteins in low concentrations, such as cysteine-rich secretory 
proteins (CRISPs), cobra venom factor and other hydrolases (serine proteinases, 
metalloproteinases, nucleotidases) (Correa-Neto et al., 2011; Kulkeaw et al., 2007; Petras et 
al., 2011). The clotting disturbances induced by some Australian elapid venoms are caused 
by procoagulant serine proteinases which are prothrombin activators (St Pierre et al., 2005) 
Venoms of snakes of the family Viperidae present large variations in their composition, but 
nevertheless the components showing the highest concentrations correspond to zinc-
dependent metalloproteinases, PLA2s and serine proteinases (Calvete, 2010; Fox & Serrano, 
2005). In addition, these venoms contain bradykinin-potentiating peptides (BPPs), 
disintegrins, C-type lectin-like proteins, L-amino acid oxidase and various other enzymes 
(Calvete et al., 2009). Metalloproteinases are largely responsible for degradation of the 
basement membrane of microvessels, with the consequent hemorrhage (Escalante et al., 
2011), activation of prothrombin and factor X (Kini, 2005; Tans & Rosing, 2001), thus 
generating the formation of microthrombi and fibrinogen depletion, i.e. defibrinogenation 
(Gutiérrez et al., 2010a), and degradation of the extracellular matrix (Moura-da-Silva et al., 
2009), among other effects. In turn, some viperid PLA2s induce acute muscle damage at the 
site of venom injection (Gutiérrez & Ownby, 2003; Lomonte et al., 2003). Some viperid PLA2s 
also exert presynaptic neurotoxicity, such as the complex ‘crotoxin’, abundant in the venom 
of South American rattlesnakes (Bon, 1997). Serine proteinases are responsible for clotting 
disturbances, i.e. defibrinogenation, and hypotension (Serrano & Maroun, 2005). Venoms 
from species of the family Atractaspididae (burrowing asps) contain sarafotoxins, which are 
low molecular mass components that induce vasospasm leading to cardiac toxicity (Bdolah, 
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2010). Finally, the venoms of snakes of the polyphyletic family Colubridae have been 
studied to a lesser extent, but they also contain metalloproteinases, serine proteinases, 
PLA2s, CRISPs and neurotoxins (Mackessy, 2002). Snake venoms present a high variability, 
not only between species, but also between different populations of the same species (Alape-
Girón et al., 2008; Chippaux et al., 1991; Jayanthi and Gowda, 1988). Moreover, some species 
present a conspicuous ontogenetic variability in the composition of their venoms, such as 
the Central American rattlesnake Crotalus simus (Calvete et al., 2010a) and the lance-head 
viper Bothrops asper (Alape-Girón et al., 2008). This high variability in venom composition 
has evident implications for the clinical manifestations of envenoming (Warrell, 1997) and 
for the preparation of antivenoms (Gutiérrez et al., 2009a).  
5. Clinical manifestations of envenoming 
The large variation occurring in venom composition urges caution when classifying the 
clinical manifestations of snakebite envenoming, since important differences have been 
described in the clinical features in envenomings by closely-related species or even within a 
single species. However, there are general trends in the clinical picture of envenoming by 
the various groups of poisonous snakes. Envenomings by elapid species (sea snakes, tiger 
snakes and taipans in Australia, cobras and kraits in Asia, cobras and mambas in Africa, and 
coral snakes in the Americas) are usually characterized by progressive descending 
neurotoxic paralysis secondary to the action of pre- or post-synaptic neurotoxins at the 
neuromuscular junctions (Warrell, 1996, 2010; White, 2010). The most serious consequence 
of this effect is respiratory paralysis, which may lead to death if not properly and timely 
attended. In addition, envenomings by a number of elapid species are also characterized by 
rhabdomyolysis, which may lead to acute renal failure (Warrell, 1996). Patients envenomed 
by elapids in Australia and Papua New Guinea develop coagulation disturbances which 
may provoke bleeding (White, 2010). On the other hand, human envenomings by some 
cobras in Asia and Africa are not characterized by neurotoxic manifestations, but instead by 
local tissue necrosis (Warrell, 1995a, 1995b).  
Viperid snake venoms provoke complex and often drastic local pathological effects, i.e. 
hemorrhage, dermonecrosis, blistering, myonecrosis and edema, always associated with pain 
(Gutiérrez & Lomonte, 2009; Warrell, 2004). These local manifestations may lead to permanent 
sequelae, such as tissue loss and dysfunction (Dart et al., 1992; Otero et al., 2002). After 
systemic venom distribution, and depending on the severity of the case, viperid snakebite 
envenomings are characterized by coagulopathies, bleeding, renal alterations and 
hemodynamic manifestations which may lead to cardiovascular shock and multisystem organ 
failure (Gutiérrez et al., 2009b; Warrell, 2004). Intravascular hemolysis might also occur, in 
some cases associated with microthrombi formation (Warrell, 1996). Exceptions to this general 
trend are envenomings by the South American and some populations of North American 
rattlesnakes, as well as some viperids in the Old World, which induce neurotoxicity (Azevedo-
Marques et al., 2009; Ferquel et al., 2007). Despite the existence of these general trends, clinical 
studies highlight the complexity of snakebite envenoming, as demonstrated by the description 
of ‘unusual’ manifestations in cases by some elapids in Asia and South America (Faiz et al., 
2010; Manock et al., 2008; Trinh et al., 2010). In addition, some venoms induce unique clinical 
features, such as the thrombotic effect described for the Caribbean viperid species Bothrops 
lanceolatus and B. caribbaeus (Thomas et al., 1996), and the acute hemorrhagic infarction of the 
pituitary in envenoming by Daboia russelli (Tun-Pe et al., 1987).  
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The severity of snakebite envenoming depends on a number of factors, such as the volume 
of venom injected, the size and physiological condition of the victim, and the region of the 
body where venom is delivered. A percentage of snakebites are not associated with venom 
injection (‘dry bites’) and, therefore, no clinical manifestations develop (Warrell, 2004). In 
general, bites in the head tend to be more severe than bites in the extremities, and 
envenoming in children are more prone to become severe. In the case of envenoming by pit 
vipers, bites in the hands are more likely to generate sequelae than bites in the lower limbs 
(Dart et al., 1992). Thus, a proper assessment of the clinical manifestations and severity of 
snakebites is a key element for the correct diagnosis and clinical management of these 
accidents. 
6. Diagnosis and treatment of snakebite envenomings 
6.1 Diagnosis 
Identification of the offending snake is often difficult because in many settings there are 
various similar species and the bitten person is usually unable to differentiate between 
them. Even when the snake is killed and brought to the health facility, identification is not 
always correct. In Australia, kits have been developed for the immunodetection of venom in 
the bite site or in urine, thus allowing the identification of the offending snake (White, 2010). 
However, this is not the case in the vast majority of regions in the rest of the world. A 
‘syndromic approach’ has been promoted for the diagnosis of the type of envenoming in 
various parts of the world (Ariaratnam et al., 2009; WHO, 2010b). For instance, in Central 
America, there are two predominant syndromes in snakebite envenomings: one presenting 
local pathological effects (swelling, pain, local tissue damage), clotting disturbances and 
bleeding, and another characterized by descending neuromuscular paralysis. The first 
syndrome is associated with envenomings inflicted by viperid species, whereas the second 
is due to envenomings by elapid species (Micrurus sp). This clinically-based diagnosis 
allows for the selection of the correct antivenom, i.e. polyvalent antivenom or anti-coral 
antivenom, respectively (Gutiérrez, 2010). Such syndromic approach has been advocated in 
other regions of the world as well, such as in sub-Saharan Africa (WHO, 2010b) and Sri 
Lanka (Ariaratnam et al., 2009). In large regions of the savannahs in sub-Saharan Africa, 
cases presenting clotting disturbances are associated with envenomings inflicted by the saw-
scale viper, Echis ocellatus (Warrell, 1995b). In this context, a simple laboratory test known as 
the ‘20 minute whole blood clotting test’ represents a useful diagnostic tool (Warrell et al., 
1974). In contrast, envenomings associated with a predominantly neurotoxic picture are 
caused by species of neurotoxic cobras (Naja sp) or mambas (Dendroaspis sp), and 
envenomings characterized by local tissue damage without coagulant disturbances are 
induced by species of Bitis or by cytotoxic cobras (WHO, 2010b).  
6.2 First aid in snakebite envenoming 
Snakebite cases in many regions of the world are initially attended by local healers who use 
a wide variety of interventions, most of which are ineffective and often exert harmful effects. 
Examples are the use of ligatures, incisions and suction, cryotherapy, electroshock, and the 
administration of synthetic or natural substances (Hardy, 2009; Warrell, 2010). Other 
interventions, such as application of ‘black stone’ or suction devices are largely ineffective 
for the removal of venom. In addition to their harmful effects, these actions delay the 
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transport of patients to health centers and, therefore, jeopardize the adequate management 
of these cases. First aid interventions should be focused on the immobilization of the bitten 
extremity and the rapid transportation to clinics or other health facilities. Communities 
should have strategies for rapid deployment of snakebitten people to medical treatment; an 
example is the use of motorcycle transportation in Nepal (Alirol et al., 2010). The interaction 
and communication of health staff with local healers is very important, in order to promote 
partnerships aimed at reducing harmful interventions and guaranteeing rapid mobilization 
for antivenom administration. The application of pressure-immobilization, by applying a 
bandage and a splint to the entire bitten limb, has been used in Australia for delaying the 
systemic absorption of neurotoxic venoms (Sutherland et al., 1979; White, 2010). Recently, a 
pharmacological intervention, based on the application of an ointment containing a nitric 
oxide donor, aimed at reducing the lymphatic absorption of venom, has been proposed 
(Saul et al., 2011), and its testing in the clinical setting is pending.  
6.3 Antivenoms: The key therapy of snakebite envenoming  
The parenteral administration of animal-derived antivenoms constitutes the mainstay in the 
therapy of snakebite envenoming (WHO, 2007a, 2010a), since the development of the first 
antivenoms, the serum anti-venimeux, during the last decade of the XIXth century (Bon, 1996). 
Antivenoms are preparations of immunoglobulins, or immunoglobulin fragments F(ab’)2 or 
Fab, obtained by fractionating the plasma of animals immunized with snake venoms 
(Gutiérrez et al., 2011a; Lalloo & Theakston, 2003; WHO, 2010a). Antivenoms can be 
monospecific, when animals receive the venom of a single species, or polyspecific, when 
venoms from two or more species are injected. The majority of manufacturers use horses for 
immunization, although few use sheep and donkeys (Gutiérrez et al., 2011a, 2011b). In most 
cases, plasma fractionation involves the digestion of proteins with pepsin or, by few 
producers, with papain, followed by the purification of antibody fragments by salting-out with 
ammonium salts or caprylic acid fractionation and, in some cases, with chromatographic 
procedures (dos Santos et al., 1989; Grandgeorge et al., 1996; Raw et al., 1991; WHO, 2010a). 
Some producers fractionate plasma with caprylic acid to obtain whole IgG preparations 
(Gutiérrez et al., 2005; Rojas et al., 1994). A detailed description of the methods used in animal 
immunization and plasma fractionation for antivenom production can be found in the WHO 
Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins (WHO, 
2010a). There are antivenom-manufacturing laboratories in every continent (a complete list can 
be found in http://apps.who.int/bloodproducts/snakeantivenoms/database/). Following 
manufacture, antivenoms are subjected to a quality control protocol which involves physical, 
chemical and biological tests aimed at ensuring the efficacy and safety of these products 
(Gutiérrez & León, 2009; WHO, 2010a).  
The ability of antivenoms to neutralize venom toxins is based on the capacity of antivenom 
antibodies, or antibody fragments, to bind and neutralize the most relevant toxins in a 
venom. It has been proposed that such neutralization is based on, at least, four mechanisms: 
(a) Binding of antibody paratopes to epitopes located at the pharmacologically-relevant 
molecular region, i.e. the catalytic active site in toxic enzymes such as phospholipases A2 
and metalloproteinases. (b) Binding of antibodies to epitopes located close to the toxin active 
site, thus exerting inhibition by steric hindrance. (c) Binding of antibodies to molecular 
regions distant from the active/toxic site of venom components, neutralization being 
achieved by allosteric changes induced in the toxins, with the consequent reduction in their 
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ability to bind to tissue or cellular targets and to cause damage. (d) Formation of 
immunocomplexes between antibodies and toxins, with the subsequent removal by 
phagocytic cells; this last mechanism does not operate in the case of antivenoms made of 
monovalent Fab fragments, since they do not form complexes (Gutiérrez & León, 2009; 
Gutiérrez et al., 2011b). 
6.3.1 Clinical performance of antivenoms: Efficacy 
Antivenoms are administered parenterally, mostly by the intravenous route, and preferably 
diluted in physiological solution. Intradermal hypersentivity tests are not recommended 
since they have a very poor predictive value (Cupo et al., 1991; Malasit et al., 1986). The 
clinical performance of antivenoms depends on several factors associated with the 
immunological and physico-chemical characteristics of these products, as well as with the 
circumstances of their use in the clinical setting. At the preclinical level, antivenoms should 
be effective in the neutralization of the most relevant toxic activities of the venoms of 
medically-relevant snakes in a particular country or region. In some cases, this is achieved 
by using antivenoms raised against the venoms of the species that provoke the bite. In other 
cases, antivenoms are able to neutralize the venoms of species not used in the immunization 
of animals, but being phylogenetically related (WHO, 2010a). This phenomenon of 
immunological cross-reactivity has been clearly demonstrated, for instance, in the case of 
antivenoms raised against Bothrops sp venoms in Latin America (Otero et al., 1995; Segura et 
al., 2010a). In other cases, however, the cross-reactivity of antivenoms is low and, therefore, 
the efficacy of some products to neutralize venoms of medically-relevant species not 
included in immunization mixtures is limited, as occurs with venoms of some rattlesnakes 
and coral snakes in the Americas (Saravia et al., 2002; Tanaka et al., 2010). This issue of low 
cross-reactivity of some antivenoms may have potentially serious implications, when some 
products are used in the treatment of envenomings by species whose venoms are 
immunologically different from the ones used in immunization. One example has been the 
use of antivenoms manufactured in India for the treatment of envenomings in sub-Saharan 
Africa (Visser et al., 2008). This problem is complicated by the frequent lack of regulation 
and quality control of imported antivenoms in many countries, thus precluding the proper 
assessment of their neutralizing ability. This issue urges upgrading the regulatory capacities 
of countries in Asia, Africa and Latin America, as to ensure that antivenoms being 
introduced in these regions are evaluated with standard preclinical tests, such as those 
recommended by the WHO (2010a).  
Antivenoms have demonstrated to be highly effective, when administered timely, at halting 
the most relevant systemic manifestations of snakebite envenoming (Gutiérrez & León, 2009; 
Lalloo & Theakston, 2003; Warrell, 1992). In the case of bites by viperids, systemic bleeding, 
hemodynamic manifestations and coagulation disturbances are controlled within hours 
after antivenom infusion. In contrast, toxins responsible for local pathological effects 
(edema, dermonecrosis, local hemorrhage and myonecrosis) are more difficult to neutralize 
by antivenoms, basically because the early onset of these effects upon venom injection, thus 
precluding an effective blockade by antivenom antibodies (Gutiérrez et al., 1998), a problem 
that is worsened by the occurrence of venom-induced vascular alterations, which affect the 
distribution of antivenom to the affected tissue (Battellino et al., 2003). In the case of 
neurotoxic venoms, characteristic of most elapid and some viperid species, the development 
of neurotoxic manifestations is prevented by the timely administration of antivenoms, with 
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the consequent neutralization of neurotoxins in the circulation before reaching 
neuromuscular junctions. However, neutralization is more difficult when neurotoxins are 
bound to receptors at the synapse. In the case of post-synaptic neurotoxins, their binding 
can be reverted (Alape-Girón et al., 1996; Boulain & Ménez, 1982), but presynaptically-acting 
toxins are known to destroy the nerve terminal, thus precluding neutralization and 
generating a more prolonged pattern of nerve damage (Prasarnpun et al., 2005). Thus, the 
clinical efficacy of antivenoms is intimately related to the ability of these products to bind 
with high affinity and neutralize relevant venom toxins located in tissues or in the 
bloodstream, as well as to the toxicokinetics of toxins and the pharmacokinetics of 
antivenom antibodies or antibody fragments (Gutiérrez et al., 2003; Scherrmann, 1994; 
WHO, 2010a). For instance, low molecular mass neurotoxins characteristic of elapid snake 
venoms are rapidly distributed and readily reach their targets in the neuromuscular 
junctions; in these cases, there is a mismatch between the toxicokinetics of these neurotoxins 
and the pharmacokinetics of antivenom antibodies (Gutiérrez et al., 2003; Ismail et al., 1998). 
On the other hand, low molecular mass Fab fragments have a relatively short half-life, thus 
resulting in the phenomenon of recurrence of envenoming, i.e. the reappearance of signs 
and symptoms of envenoming several hours after antivenom therapy (Ariaratnam et al., 
1999; Boyer et al., 2001; Meyer et al., 1997). Careful clinical following up of patients is 
necessary to determine the need of an additional dose of antivenom.  
The rapid access to effective antivenoms constitutes a key issue in the proper management 
of snakebite envenoming. If the envenoming is potentially severe, and if the access to 
antivenom is delayed, due to reasons that range from hesitation to use antivenoms to 
prolonged transportation times to health facilities and lack of antivenoms in health posts, 
the efficacy of antivenoms is jeopardized and various pathophysiological complications 
might ensue. Another factor that determines the efficacy of antivenom treatment has to do 
with the use of a correct dose of this immunobiological, and to the assessment of whether 
the patient needs an additional dose of antivenom, based on the evolution of clinical and 
laboratory parameters. These considerations demand that the health staff in charge of 
treating these envenomings have an adequate knowledge of the basic elements of 
antivenom usage. 
6.3.2 Antivenom safety 
Administration of antivenom is associated, in a variable percentage of cases, with early and 
late adverse reactions. Early adverse reactions (EARs) can be, in few cases, truly 
anaphylactic reactions, i.e. IgE-mediated, or, alternatively, anaphylactoid reactions, which 
occur more frequently, and are de novo reactions not mediated by previous exposure to 
horse proteins (Warrell, 1995a). The mechanisms of these reactions are not well understood, 
but are likely to depend on (a) complement activation by antibody aggregates present in 
antivenom (Sutherland, 1977); (b) formation of complexes between human heterophylic 
antibodies against antivenom antibodies, with consequent complement activation (León et 
al., 2008); or (c) presence of antibodies in antivenoms that react with cells, such as 
erythrocytes (León et al., 2007), leukocytes or endothelial cells, thus provoking adverse 
reactions. Such EARs can be mild, characterized by urticaria and itching only, or severe, 
involving angioedema, bronchospasm and hypotension (Warrell, 1995a). The incidence of 
EARs varies significantly among different antivenoms, from as low as 5% to higher than 
70% of the cases with some products (Chippaux et al., 1998; Gawarammana et al., 2004; 
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Otero-Patiño et al., 1998). Such high variability is due to the different physicochemical 
quality of antivenoms, since some products have high protein concentration and high 
amounts of protein aggregates. Therefore, the physicochemical features of antivenoms 
greatly determine their safety profile, an issue that demands renewed efforts at the 
technological and regulatory levels. Another type of reaction observed in some antivenoms 
are pyrogenic reactions, associated with chills and fever (WHO, 2010b), but these should be 
avoided by a proper quality control, i.e. pyrogenicity testing, of these products. In the event 
of EARs, antivenom infusion should be stopped, and the reaction treated with adrenaline, 
anti-histamines and steroids (Warrell, 1995a). Once the reaction is controlled, antivenom 
infusion should be continued. Pretreatment with adrenaline has been advocated for 
reducing the incidence of EARs (de Silva et al., 2011). Late adverse reactions (LARs) to 
antivenoms occur 5-24 days after treatment, and are characterized by itching, fever, 
urticaria, arthralgia and proteinuria (Warrell, 1995a). This corresponds to a typical type III 
hypersensitivity reaction, i.e. serum sickness, due to the formation of immune complexes 
between antivenom antibodies and antibodies generated in the patient against antivenom 
proteins. The incidence of serum sickness after antivenom administration correlates with the 
amount of foreign protein, i.e. antivenom, administered (LoVecchio et al., 2003). LARs are 
treated with anti-histamines and steroids.  Another aspect of antivenom safety that has to be 
considered is microbial safety, which is guaranteed by sterile filtration of the final product 
and the use of viral inactivation/removal steps (Burnouf et al., 2004; WHO, 2010a). Some of 
the manufacturing steps currently used in antivenom production inactivate or remove 
viruses, thus contributing to the microbial safety of these products (Burnouf et al., 2004; 
WHO, 2010a).  
Such high heterogeneity in the safety of antivenoms, in terms of incidence of adverse 
reactions, calls for international cooperative efforts aimed at improving the technological 
platform of many antivenom producers, in order to increase the physicochemical quality of 
antivenoms on a world wide basis (Gutiérrez et al., 2011a). A number of antivenom 
producers in Asia, Africa and Latin America need to upgrade their facilities and protocols. 
The experience gained by well-developed antivenom manufacturing laboratories in various 
parts of the world should contribute to the improvement of less developed antivenom 
producers, through a variety of activities such as technology transfer programs, workshops, 
training and exchanges of various sorts. Such networking scenario should be promoted by 
the WHO and its regional offices, and by organizations such as the Global Snake Bite 
Initiative (www.snakebiteinitiative.org/).  
6.4 Ancillary treatments 
The therapy of snakebite envenoming includes a series of interventions in addition to 
antivenom administration. In the case of viperid venoms, hemodynamic and renal 
disturbances demand careful control of fluid therapy, monitoring of central venous 
pressure, and use of diuretics (Warrell, 1995a; WHO, 2010b). Infection often develops in 
viperid snakebites and requires the use of antibiotics. Moreover, local tissue damage by 
viperid and some elapid snakebites calls for debridement of necrotic tissue and care of the 
bitten limb. In some cases, when muscle intracompartmental pressures increase beyond 45 
mm Hg, compartment syndrome ensues and fasciotomy is indicated (WHO, 2010b). In the 
case of neurotoxic envenomings caused by elapid and some viperid species, mechanical 
ventilation should be provided in the event of respiratory paralysis (Warrell, 1995a; WHO, 
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2010b). The complexity of snake venoms and the corresponding variability in the clinical 
presentation of these envenomings complicates the management of the cases and demands 
an adequate training of the health staff in charge of treating these emergencies, in order to 
guarantee the implementation of effective therapeutic interventions.  
The poor efficacy of antivenoms to neutralize local tissue damage induced by viperid and 
some elapid venoms brings the need to find alternative therapies. A very promising avenue 
is the possibility of using natural or synthetic inhibitors of venom toxins, such as inhibitors 
of phospholipases A2, metalloproteinases and hyaluronidases, for blocking the action of 
tissue-damaging toxins by rapidly administering these inhibitors directly on the site of 
venom injection (Gutiérrez et al., 2007; Lomonte et al., 2009; Perales et al., 2005). Such 
possibility has been tested, with excellent results, at the preclinical level in mouse models 
(Borkow et al., 1997; Lomonte et al., 2009; Rucavado et al., 2000; Yingprasertchai et al., 2003). 
It is necessary to identify and develop inhibitors, some of which may be already in use for 
other pathologies, and to test them at the preclinical and clinical levels. The therapy of 
snakebite envenoming in the future will likely involve, in addition to intravenous 
antivenom administration, the local injection of toxin inhibitors, as well as other ancillary 
interventions aimed at controlling the systemic aspects of envenoming and to modulate the 
deleterious aspects of the inflammatory response of the organism to snake venoms 
(Gutiérrez et al., 2007).  
7. Preclinical and clinical testing of antivenoms 
The large intra- and interspecies variability in the composition of snake venoms poses a 
problem for antivenom efficacy, since cross-neutralization of antivenoms against venoms 
not used in the immunizing mixture might not occur. Therefore, the distribution of 
antivenoms to countries or regions where medically-relevant snakes are different from those 
used in immunization schemes needs to be carefully evaluated in order to ensure that these 
antivenoms are indeed effective. This issue gets complicated by the fact that, quite often, 
regulatory agencies in developing countries do not have the facilities and expertise to 
perform adequate preclinical testing of the antivenoms being imported (D. Williams et al., 
2011). A proper assessment of antivenom efficacy should be based on preclinical and clinical 
testing. At the preclinical level, it is necessary to assess the capacity of antivenoms to 
neutralize the lethal, as well as other relevant toxic activities, of the most important venoms 
in a country or region. This demands, in the first place, the establishment of local facilities to 
collect and keep medically-relevant snakes. These snake colonies should provide pools of 
venoms, which could then be used in preclinical testing of antivenoms. Precise indications 
on how to built and run these facilities are included in the WHO Guidelines for Antivenom 
Production, Control and Regulation of Antivenoms (WHO, 2010a). In the case of viperid 
venoms, a battery of preclinical tests usually includes the evaluation of the neutralization of 
lethal, hemorrhagic, coagulant, defibrinogenating and myotoxic activities (Gutiérrez et al., 
2011b; Theakston, 1986; WHO, 2010a). In the case of elapid snakes, antivenom preclinical 
efficacy should be assessed by the neutralization of lethality and, in the case of elapid 
venoms that induce necrosis or coagulopathy, by the neutralization of dermonecrosis and 
coagulant activities, respectively (Gutiérrez et al., 2011b; WHO, 2010a). These methods 
involve simple laboratory procedures that need to be implemented in countries where 
antivenoms are being produced or imported. In addition, international collaborative 
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projects, involving well-developed laboratories, could be implemented in order to test 
antivenoms (D. Williams et al., 2011). More recently, a proteomic approach, named 
‘antivenomics’, has been adapted for the evaluation of immune reactivity of antivenoms 
against particular toxins in venoms (Calvete, 2010; Gutiérrez et al., 2009a; Lomonte et al., 
2008). This methodology allows for the identification of the toxins recognized by antivenom 
antibodies. 
The preclinical assessment of antivenoms should be followed by clinical evaluation of 
antivenom safety and efficacy (WHO, 2010a). Since phase I clinical trials in healthy 
volunteers are ethically unacceptable in the case of antivenoms, because they might induce 
adverse reactions, a substitution of phase I clinical trial, by a protocol known as ‘3 + 3 dose 
escalation design’, has been proposed for antivenoms (S.B. Abubakar et al., 2010b). This is 
then followed by phase III clinical trials in which a new antivenom is compared with an 
existing antivenom of known efficacy and safety (see for example the studies of I.S. 
Abubakar et al., 2010; Cardoso et al., 1993; Otero et al., 1999; Otero-Patiño et al., 1998; 
Smalligan et al., 2004; Warrell et al., 1974). Clinical trials should use robust clinical and 
laboratory end points for the assessment of therapeutic success. Furthermore, post-
marketing surveillance (pharmacovigilance) is required to detect possible adverse reactions 
not reported in the clinical trials and to follow up efficacy (WHO, 2010a).  
8. Technological aspects for antivenom improvement 
The need to have antivenoms of wide cross-reactivity, able to neutralize venoms from as 
many snake species as possible, demands a careful revision of the design of venom 
mixtures used for immunization of animals. There is a large body of knowledge in the 
biochemistry, toxicology and immunology of snake venoms, especially of venoms from 
species having a heavy medical impact, which should be used for the re-evaluation of the 
immunizing mixtures and for the design of novel mixtures for new antivenoms (Gutiérrez 
et al., 2009a; D. Williams et al., 2011). Proteomics technologies, together with 
neutralization tests, constitute valuable tools to analyze venom composition and effects, 
and to assess the neutralizing profile of current and new antivenoms. The Global Snake 
Bite Initiative has proposed a strategy to structure an international collaborative effort to 
evaluate current antivenoms and to design improved antivenoms (D. Williams et al., 
2011). One aspect of this strategy is based on the development of regional polyspecific 
antivenoms for use in sub-Saharan Africa and Asia using clinical, phylogenetic, proteomic 
and antivenomic analyses for the selection of the best venom mixtures for immunization. 
These antivenoms, manufactured by several laboratories, will then be evaluated by 
independent preclinical assessment, followed by clinical trials in various countries, 
performed by local medical personnel. In parallel, international expert committees will 
validate production facilities for prequalification, in a process aimed at ensuring the 
manufacture of the volume of antivenom needed in those regions (D. Williams et al., 
2011).   
One example of the potential usefulness of such an approach has to do with the design of 
immunizing mixtures for antivenoms to be used in sub-Saharan Africa. Several antivenoms 
use a mixture of venoms from many species; however, a recently developed antivenom was 
produced by using a mixture of venoms from only three species (Gutiérrez et al., 2005). 
Neutralization and antivenomic studies have shown that this new antivenom is able to 
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neutralize the venoms of several species of viperids and spitting cobras from sub-Saharan 
Africa (Calvete et al., 2010b; Segura et al., 2010b; Petras et al., 2011). Similarly, the ideal 
venom mixtures for antivenoms to be used in some parts of Asia need to be re-assessed on 
the basis of recent clinical evidence of the existence of medically-relevant species whose 
venoms are not routinely used in antivenom manufacture, such as that of the viperid 
Hypnale hypnale (Ariaratnam et al., 2008). Likewise, the decision on whether to prepare 
monospecific or polyspecific antivenoms has to be based on sound epidemiological, clinical, 
biochemical and immunological evidence. Consequently, the design and re-design of venom 
mixtures for immunization requires a multidisciplinary approach. On the other hand, there 
are other aspects of antivenom technological development that should be considered, such 
as stability and improved immunization schemes. Liquid antivenoms have to be stored at  
2-8 ºC (WHO, 2010a). However, the quality of the cold chain in many regions of the world is 
poor, thus complicating the distribution of antivenoms, especially to rural settings where 
most snakebites occur. This problem can be overcome by producing freeze-dried 
antivenoms, but this increases the production cost and, therefore, the price. Alternatives are 
being explored aimed at formulating liquid antivenoms stable at room temperature 
(Rodrigues-Silva et al., 1999; Segura et al., 2009). Likewise, the design of immunization 
protocols based on multi-site injection of small volumes containing low amounts of venom 
has resulted in higher neutralizing titers with very little damage to the immunized animals 
(Chotwiwatthanakun et al., 2001). Furthermore, the search for novel adjuvants is a relevant 
task in the efforts to improve antivenom antibody titers (Gutiérrez et al., 2011a). 
9. The accessibility and correct use of antivenoms 
Despite the widespread demonstration of antivenom efficacy for the treatment of snakebite 
envenoming, and the fact that many aspects of the know-how required to produce 
antivenoms are freely available (WHO, 2010a), there is a current deficit in antivenom 
accessibility in various regions of the world, most notably in sub-Saharan Africa and some 
countries of south-east Asia (Chippaux, 2010; Theakston et al., 2003; D. Williams et al., 2011; 
WHO, 2007a). This phenomenon has multiple causes, such as: (a) Withdrawal of some 
manufacturers from these markets due to profit considerations. (b) Privatization of former 
public laboratories, with the consequent increments in the prices of antivenoms. (c) The 
impact of international policies designed to reduce the size of the public sector, including a 
reduction in the provision of public health services and their privatization. (d) Weakening of 
antivenom manufacturing laboratories of the public sector in many developing countries, 
associated with lack of investment in facilities and technology, and reduction in training 
programs for the staff. (e) Lack of financial support for antivenom purchase by ministries of 
health, due to economic constraints and to prioritization on other health issues perceived as 
more pressing needs. (f) Loss of confidence in antivenom treatment in some regions due to 
the use of antivenoms of poor efficacy or safety. (g) Poor advocacy for promoting greater 
attention to snakebite envenoming as a neglected tropical disease. (h) Low profile of 
snakebite envenoming in the international public health agenda. As a result, antivenom 
accessibility is deficient in vast regions of Asia and Africa (WHO, 2007a; D. Williams et al., 
2011). The solution to this complex problem demands concerted actions at various levels, 
from the technological and manufacturing realm to the public health arena (Chippaux, 2010; 
Gutiérrez et al., 2010b; D. Williams et al., 2010, 2011). 
www.intechopen.com
 
Public Health – Methodology, Environmental and Systems Issues 
 
146 
9.1 How to enhance the accessibility of antivenoms 
Economic and political constraints constitute one of the main causes of poor accessibility of 
antivenoms in many countries. It is evident that the sole drive of the market forces will not 
solve this problem and, instead, well-designed strategies with a strong participation of 
governments and non-governmental organizations have to be implemented. This is a critical 
aspect that needs to be addressed by a variety of interventions such as: (a) Increasing the 
technological capacity of manufacturing laboratories in developing countries, both in the 
public and private realms, and introduction of cost-effective methodologies for antivenom 
production. One example is the manufacture of whole IgG antivenoms by caprylic acid 
fractionation of plasma (Gutiérrez et al., 2005; Rojas et al., 1994). This procedure generates 
antivenoms of high quality and high yield, at reduced production costs, thus constituting an 
excellent alternative for low-income countries (Brown & Landon, 2010). (b) Increased 
recognition of governments of low-income countries on the impact of snakebite envenoming 
as a public health problem, with the consequent political and financial decisions for the 
acquisition of adequate volumes of antivenom. (c) Using the capacity of large antivenom 
producers in order to manufacture antivenoms for other regions of the world at reasonable 
prices. This could be accomplished by promoting international partnerships between 
manufacturers, public health authorities, organizations of the civil society, and donors, 
similarly to what has been done for other neglected tropical diseases (Hotez et al., 2006). (d) 
Promoting strategies for price reduction, such as differential pricing arrangements or large 
scale ‘pooled’ purchases for various countries (Gutiérrez et al., 2010b).  
9.2 Distribution of antivenoms: guaranteeing access to regions where snakebites 
occur 
Even if governments purchase adequate volumes of antivenom, this does not guarantee that 
these drugs will reach the rural health posts where most snakebite envenomings occur. This 
problem has diverse roots, such as: (a) Incomplete information on the epidemiology of 
snakebites. In countries where official statistics of snakebite incidence are lacking or 
incomplete, the decision on where to distribute antivenoms cannot be taken on a rigorous 
base. This is another reason for underscoring the relevance of proper epidemiological 
register of this pathology. (b) Antivenom acquisition procedures by the ministries of health 
in many countries are slow and cumbersome; moreover, due to budgetary constraints, the 
volumes of antivenom purchased are often insufficient; both of these factors preclude the 
distribution of adequate volumes of this drug to rural settings. (c) Antivenoms are often 
distributed only to hospitals and clinics in large cities, distant from the regions where the 
majority of snakebites occur, thus affecting the timely treatment of patients. (d) As discussed 
previously, the lack of an adequate cold chain system in many rural settings of the world 
precludes the effective distribution of antivenoms. (e) Many rural regions are devoid of 
healthcare facilities, thus affecting the access to antivenom and other medical interventions 
and forcing people to travel large distances to receive medical attention.  
This complex scenario demands the design of well-structured and effective strategies of 
antivenom distribution, on the basis of sound epidemiological information on snakebite 
incidence. An intersectorial and interprogrammatic approach should be promoted, in 
conjunction with other efforts being performed in the public health realm, in order to favour 
a synergy with other actors and projects, with the consequent impact in the cost-
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effectiveness of interventions (WHO, 2007c). The compulsory report of snakebite 
envenoming (WHO, 2010a) and the use of geographical information systems to identify high 
risk areas (Hansson et al., 2010; Leynaud & Reati, 2009) would greatly contribute to generate 
a solid basis of information on the actual magnitude of the problem. Furthermore, the 
awareness of national and regional health authorities on the impact of snakebite 
envenoming should be promoted by academic, public health and civil society organizations, 
in order to ensure the acquisition and distribution of the required volumes of antivenom. 
Likewise, antivenom distribution strategies should benefit from the use of the cold chain 
system already developed for vaccine distribution. Also, the provision of antivenom access 
to rural settings and the training of rural health staff in the correct administration of 
antivenoms should be prioritized. Interventions tailored to the conditions of each country 
and region should be promoted, in order to optimize the available resources and guarantee 
a rapid access to treatment (see for example Otero et al., 1992).  
9.3 Promoting the correct use of antivenoms 
The distribution of antivenoms to regions where snakebites occur should be complemented 
by a proper training of health staff in the correct usage of this product and in the proper 
treatment of snakebite envenomings. There is evidence of poor knowledge of medical and 
nursing staff in various regions of the world on how to diagnose and treat snakebite 
envenomings, how to use antivenoms, and how to treat possible adverse reactions to their 
administration (Gutiérrez et al., 2009c; Simpson, 2008). This requires concerted efforts at 
medical and nursing schools in the universities, as well as the implementation of permanent 
educational programs on this subject, particularly aimed at rural health facilities. Likewise, 
the implementation of teaching material and the development of guidelines for the 
diagnosis and treatment of snakebite envenomings should be actively promoted, both at 
regional (WHO, 2010b) and national levels. These tasks should involve not only teaching 
institutions, but also public health authorities, local organizations of the civil society, and 
antivenom manufacturers. The critical revision of antivenom prospects, on the basis of 
current knowledge on the taxonomy of snakes and on the clinics of snakebite envenomings, 
are of great relevance, in the light of evident misconceptions included in the prospects of 
some antivenoms (Simpson & Norris, 2007).  
10. Prevention of snakebites 
Prevention programs aimed at reducing the impact and incidence of snakebite envenomings 
should be a priority in the international efforts required to confront this problem. The 
design of these programs should be tailored to the cultural, social, economic and 
institutional characteristics of the populations, and should involve the active participation of 
the communities in their design and implementation. Impoverished and excluded groups, 
such as indigenous communities in many parts of the world, should receive particular 
attention. The design of these programs should be also based on sound social science 
research aimed at understanding the particularities and needs of each region and context, 
with the participation of the communities. It is highly relevant, for instance, to understand 
how the problem is perceived in the community and what types of preventive interventions 
are suited for each particular context. Likewise, specific strategies should be designed for 
situations involving natural disasters, as snakebites have been reported to increase in such 
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circumstances. In addition, the natural history of envenomings should be considered, 
including the distribution of snakes in various types of crops and the behaviour of snakes. In 
some regions of Asia, bites by kraits (genus Bungarus) often occur at nights inside human 
dwellings while people are asleep on the ground (Sharma et al., 2004). The use of mosquito 
nets has reduced the incidence of envenoming by kraits in Nepal (Chapuis et al., 2007). The 
majority of viperid snakebites occur in the feet; thus, a preventive measure should be the 
use of footware (Alirol et al., 2010; Gutiérrez, 2010; Warrell, 2010).  
11. Final remarks: The need for an integrated approach and for the promotion of 
partnerships 
The world wide efforts required to reduce the impact of snakebite envenoming should be 
conceptualized within the frame of the Millennium Development Goals (MDGs) 
(http://www.un.org/millenniumgoals/global.shtml), particularly regarding the provision 
of access to essential drugs (WHO, 2011), in this case antivenoms, to developing countries. 
The access to adequate health services is a human right, and states and other international 
instances have the obligation to ensure the access to health facilities, goods and services on a 
non-discriminatory basis, especially to vulnerable and marginalized groups, and to provide 
education and access to information to the communities on relevant health issues, such as 
snakebite envenoming. Therefore, interventions aimed at ameliorating the impact of this 
pathology should be viewed within a frame of human rights and social responsibility of 
states, international organizations and non-governmental groups. 
Snakebite envenoming is a ‘tool-ready’ disease, in the sense that the basic technological 
therapeutic tools to treat this pathology, i.e. antivenoms, are available. However, there is a 
need to implement renewed efforts to improve the quality of some antivenoms, to design 
new antivenoms for various regions in the world, and to increase the volume of production 
as to fulfil the world wide needs to these immunobiologicals. Scientific, technological and 
public health tasks include acquisition of more rigorous data on the incidence of snakebite 
incidence and mortality, assessment of preclinical and clinical performance of currently 
available antivenoms, and development of novel antivenoms on the basis of 
epidemiological, biochemical, toxicological and immunological knowledge on venoms. 
Moreover, the strengthening of antivenom manufacture on a global basis should involve an 
active process of technology transfer and training aimed at improving the current 
technological platform of many antivenom producers, especially those located in developing 
countries. Finally, renewed efforts should be undertaken to guarantee the deployment and 
effective distribution and use of antivenoms to the regions of the world where this 
pathology has its highest impact. Table 1 summarizes some of the most pressing tasks that 
need to be promoted as part of a global strategy to reduce the impact of snakebite 
envenomings. 
The design of effective strategies to confront this problem should be also integrated with the 
more general efforts in the arena of neglected tropical diseases (WHO, 2007c). Such strategies 
should be conceived from an intersectorial and interprogrammatic perspective (see WHO, 
2007c), with a synergistic approach involving the control of other neglected tropical diseases; 
such an approach will significantly increase the cost-effectiveness of interventions. Areas of 
possible interprogrammatic cooperation include: (a) The collaborative delivery of antivenoms 
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within distribution channels already developed for other immunobiologicals, such as vaccines. 
(b) Incorporating antivenoms in integrated drug purchasing schemes in developing countries 
on a regional basis. (c) Strengthening the development of public health systems in remote rural 
areas where snakebite envenomings are frequent. (d) Promoting partnerships of diverse sorts 
with groups involved in the combat of neglected tropical diseases, such as foundations, non-
governmental organizations and other advocacy groups. (e) Including snakebite envenoming 
in the agenda of organizations that provide financial support for research and intervention 
programs for neglected tropical diseases in developing countries. (f) Incorporating the subject 
of snakebite prevention, diagnosis and treatment within the context of educational packages 
on neglected tropical diseases in teaching institutions, public health facilities and communities. 
(g) Promoting the inclusion of the subject of snakebite envenoming within the agenda of 
community organizations for the promotion of health in rural areas of countries in Africa, Asia 
and Latin America.  
 
1. Acquisition of reliable information on snakebite incidence and mortality 
2. Innovation in the technology for the production of antivenoms 
3. Strengthening the capacity of laboratories in low-income countries to manufacture 
and control antivenoms  
4. Commitment of manufacturers to produce antivenoms for regions devoid of local 
production 
5. Implementation of economic strategies to ensure the sustainable production of 
antivenoms 
6. Improvement of the national regulatory expertise and quality control of 
antivenoms in low-income countries 
7. Accessibility of antivenoms at affordable prices in low-income countries 
8. Preclinical and clinical assessment of antivenom efficacy and safety 
9. Development of effective antivenom distribution programs to regions of high 
incidence of snakebites 
10. Permanent training programs for health staff on snakebite envenomings and their 
treatment 
11. Development of programs to support people suffering from sequelae of snakebite 
envenomings 
12. Preventive and educational programs at the community level with involvement of 
local organizations 
Table 1. Summary of some of the most important tasks for an integrated strategy to confront 
the problem of snakebite envenoming from a global perspective. Adapted from Gutiérrez et 
al. (2010b) 
In the long term, the reduction of the impact of snakebite morbidity and mortality, with its 
drastic effects on the quality of human life, should involve a global partnership 
incorporating many different actors at various levels in our societies, such as: (a) The 
scientific (‘epistemic’) community of toxinologists, represented by the International Society 
on Toxinology (IST) and researchers in every continent. (b) Groups working on 
technological development and technology transfer activities, both in the pharmaceutical 
industry and in university departments. (c) Antivenom manufacturers. (d) International 
health organizations, especially the WHO and its regional offices. (e) National public health 
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authorities, i.e. Ministries of Health and other organizations of the public health sector. (f) 
National regulatory bodies, responsible for ensuring the safety and efficacy of antivenoms 
being distributed. (g) Non-governmental organizations (NGOs) and advocacy groups that 
promote a public health agenda and the access of essential drugs to developing countries. 
(h) Organizations of the civil society of countries having a high burden of snakebite 
envenoming (Figure 2). The current tasks of generating a growing international awareness 
on the magnitude of this problem, establishing partnerships to ensure the development, 
availability and accessibility to antivenoms, and promoting prevention and an effective 
clinical management of this pathology, are being promoted by the Global Snake Bite 
Initiative (GSI), the WHO, and a number of national and regional projects in various parts of 
the world.  
 
Fig. 2. Some of the participants that should be involved in a global partnership aimed at the 
reduction of the impact of snakebite envenoming in the world. 
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